Cencora, Inc.

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cencora, Inc. and other ETFs, options, and stocks.

About COR

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. 

CEO
Robert P. Mauch
CEORobert P. Mauch
Employees
51,000
Employees51,000
Headquarters
Conshohocken, Pennsylvania
HeadquartersConshohocken, Pennsylvania
Founded
1947
Founded1947
Employees
51,000
Employees51,000

COR Key Statistics

Market cap
66.89B
Market cap66.89B
Price-Earnings ratio
19.89
Price-Earnings ratio19.89
Dividend yield
0.67%
Dividend yield0.67%
Average volume
1.59M
Average volume1.59M
High today
$357.28
High today$357.28
Low today
$349.70
Low today$349.70
Open price
$350.13
Open price$350.13
Volume
1.11M
Volume1.11M
52 Week high
$377.54
52 Week high$377.54
52 Week low
$244.82
52 Week low$244.82

Stock Snapshot

The current Cencora, Inc.(COR) stock price is $350.56, with a market capitalization of 66.89B. The stock trades at a price-to-earnings (P/E) ratio of 19.89 and offers a dividend yield of 0.67%.

On 2026-11-17, Cencora, Inc.(COR) stock moved within a range of $349.70 to $357.28. With shares now at $350.56, the stock is trading +0.2% above its intraday low and -1.9% below the session's peak.

Trading volume for Cencora, Inc.(COR) stock has reached 1.11M, versus its average volume of 1.59M.

The stock's 52-week range extends from a low of $244.82 to a high of $377.54.

The stock's 52-week range extends from a low of $244.82 to a high of $377.54.

COR News

TipRanks 16h
Cencora price target raised to $400 from $395 at Wells Fargo

Wells Fargo raised the firm’s price target on Cencora (COR) to $400 from $395 and keeps an Overweight rating on the shares. The firm says momentum in Q4 2026 re...

TipRanks 4d
FTC sues to block Covetrus acquiring MWI from Cencora

The Federal Trade Commission sued to block Covetrus and its owners, Clayton, Dubilier & Rice and TPG Inc., from acquiring its closest competitor, MWI Veterinary...

Reuters 4d
US FTC sues to block Cencora's $3.5 billion sale of veterinary unit to Covetrus - Reuters

...

US FTC sues to block Cencora's $3.5 billion sale of veterinary unit to Covetrus - Reuters

Analyst ratings

65%

of 17 ratings
Buy
64.7%
Hold
35.3%
Sell
0%

More COR News

Simply Wall St 6d
Should Profit Rebound Require Action From Cencora Investors?

Cencora reported fourth quarter and full year 2026 results, with sales of US$88.35b for the quarter and US$337.40b for the year, alongside a move from a prior n...

Should Profit Rebound Require Action From Cencora Investors?

People also own

Based on the portfolios of people who own COR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.